Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report published on Monday. The firm issued a sell rating on the stock.

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st.

Can-Fite BioPharma Trading Up 5.8 %

Can-Fite BioPharma stock opened at $1.47 on Monday. The company has a fifty day simple moving average of $1.60 and a 200-day simple moving average of $2.12. The stock has a market cap of $5.20 million, a P/E ratio of -0.82 and a beta of 1.33. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers grew its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.